Herbalife's Aloin Identification Method for Aloe Vera Officially Recognized by AOAC INTERNATIONAL
LOS ANGELES, June 11, 2025--(BUSINESS WIRE)--Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform, today announced the Association of Official Analytical Collaboration (AOAC INTERNATIONAL)—a global authority in analytical science—has formally certified its proprietary method for identifying and measuring anthraquinones, also known as aloins, in aloe vera. Aloe regulatory groups require producers of ingestible aloe vera products to monitor naturally occurring compounds such as aloin A, aloin B, and aloe-emodin to meet safety guidelines. This certification officially recognizes Herbalife's longstanding method as the world's first AOAC-approved approach for detecting aloins—reinforcing safety and quality benchmarks across botanical and dietary supplement industries.
Developed by Herbalife scientists and validated by independent laboratories worldwide, this AOAC-certified method is used to test every batch of Herbalife's aloe-based products, ensuring safety, while preserving aloe vera's natural benefits. Aloe vera is a key ingredient in many of Herbalife's top products, which are sold in more than 90 markets.
"This AOAC validation is an important milestone for Herbalife and the industry as a whole," said Gary Swanson, SVP of Global Quality at Herbalife and lead author of the study. "We are proud to lead scientific innovation that enhances botanical ingredient safety, benefitting not only Herbalife products and our customers, but also advancing standards across the industry."
Herbalife's method was validated through a global multi-laboratory study involving eight independent laboratories. Each lab tested the same set of six aloe vera samples, including both raw materials and finished products, using HPLC (High-Performance Liquid Chromatography) to measure aloin A, aloin B, and aloe-emodin. The study ensured the method's accuracy and reliability across various labs and product types, with results confirming that it met all performance criteria, including precision and system suitability.
"This multi-laboratory validation study supported approval of an analytical method developed by Herbalife scientists as the AOAC 2016.09 Official Final Action Method," said Dr. Katerina Mastovska, deputy executive director and chief science officer, AOAC INTERNATIONAL. "AOAC official methods undergo rigorous scientific evaluation and are highly credible and globally accepted. As such, this method will help strengthen botanical quality and safety standards worldwide."
Herbalife has a long-standing commitment to aloe vera research and quality assurance. This dedication has resulted in five patents and three published studies focused on developing safe extraction methods that preserve the plant's natural benefits. While many companies rely solely on supplier certifications to confirm the authenticity of their aloe vera, Herbalife goes further. The company is one of the few in the world using advanced proton nuclear magnetic resonance (NMR) spectrometry—an analytical technique that uses magnetic fields and radio waves to identify the molecular structure of raw materials. This allows Herbalife to independently verify the identity and purity of its aloe vera at the molecular level, ensuring the highest standards of quality, consistency and traceability across its global supply chain.
For 45 years, Herbalife has upheld a global commitment to quality through its rigorous Seed to Feed process. This comprehensive system ensures that every ingredient—from responsibly sourced crops cultivated by dedicated farmers to the finished product—meets stringent standards for identity, potency, safety, and purity. Herbalife performs internal testing in ISO 17025-accredited laboratories, verifying that ingredients comply with both company standards and government regulations. The company's science-backed approach, grounded in Good Manufacturing Practices (GMPs) and NSF International standards, delivers consistent, transparent products in more than 90 markets. Supported by a global team of scientists and quality experts, this process strengthens consumer trust and continues to advance industry standards worldwide.
Herbalife's aloe vera testing method has been published in Journal of AOAC INTERNATIONAL (Volume 108, Issue 3, Pages 449-471).
About Herbalife Ltd.
Herbalife (NYSE: HLF) is a premier health and wellness company, community and platform that has been changing people's lives with great nutrition products and a business opportunity for its independent distributors since 1980. The Company offers science-backed products to consumers in more than 90 markets through entrepreneurial distributors who provide one-on-one coaching and a supportive community that inspires their customers to embrace a healthier, more active lifestyle to live their best life.
For more information, visit https://ir.herbalife.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250611798277/en/
Contacts
Media Contact: media@herbalife.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Bragar Eagel & Squire, P.C. Reminds Investors in Bitfarms or Reddit of The Class Action Lawsuits Filed and Urges Investors to Inquire About Their Rights
Bragar Eagel & Squire, P.C. Litigation Attorney Brandon Walker Encourages Investors Who Suffered Losses In Bitfarms (BITF) or Reddit (RDDT) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648 NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bitfarms Ltd. (NASDAQ: BITF) and Reddit, Inc. (NYSE:RDDT). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Bitfarms Ltd. (NASDAQ: BITF) Class Period: March 21, 2023 and December 9, 2024 Lead Plaintiff Deadline: July 8, 2025 The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Bitfarms maintained deficient internal controls over financial reporting; (ii) as a result, the Company incorrectly categorized proceeds derived from the sale of digital assets as a cash flow from operating activities rather than as a cash flow from investing activities; (iii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weakness in its internal controls over financial reporting related to its classification of the 2021 Warrants; (iv) the foregoing errors caused Bitfarms to misstate various items in several of the Company's previously issued financial statements; (v) as a result, these financial statements were inaccurate and would likely need to be restated; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times For more information on the Bitfarms class action go to: Reddit, Inc. (NYSE:RDDT) Class Period: October 29, 2024 and May 20, 2025 Lead Plaintiff Deadline: August 18, 2025 The complaint alleges that the social media website Reddit receives a significant portion of its user traffic from Google Search, and Reddit's primary source of revenue is generated from advertising to users on its own platform. Throughout the relevant period, Google Search began implementing new Artificial Intelligence ('AI') capabilities such as AI Overview that could change the nature of search results. Defendants are alleged to have made false and misleading statements, and failed to disclose, that: (i) changes in Google Search's algorithm and features like AI Overview were causing users to stop their query on Google Search; (ii) these algorithm changes were materially different than prior instances of reduced traffic to the Reddit website; (iii) Defendants were aware that the increase in the query term 'Reddit' on search engines was because users were getting the sought after answer from Google Search without having to go to Reddit, and not because they intended to visit Reddit; (iv) this zero-click search reality was dramatically reducing traffic to Reddit in a manner the Company was unable to overcome in the short term; and (v) Defendants, therefore, lacked a reasonable basis for its outlook on user rates and advertising revenues. On May 1, 2025, after the market close, Reddit issued an earnings release announcing its first quarter 2024 financial results for the period ending March 31, 2025. The earnings release revealed that Reddit had experienced three consecutive quarters of deceleration in daily active user growth. On this news, the price of Reddit's common stock fell $4.96 per share, or 4.2%, from a closing price of $118.79 per share on May 1, 2025, to a closing price of $113.83 per share on May 2, 2025. Then, on May 19, 2025, Wells Fargo analysts downgraded Reddit's stock and lowered their price target to $115 per share from a previous $168 per share. Wells Fargo called Google Search's implementation of new AI features as likely 'permanent' disruptions on user traffic for Reddit. On this news, the price of Reddit's common stock fell $5.24 per share, or 4.6%, from a closing price of $113.23 per share on May 16, 2025, to a closing price of $107.99 per share on May 19, 2025. Finally, on May 21, 2025, Baird analysts substantially downgraded Reddit's stock, reducing the price target to $120 per share from the previous $140 per share. Citing similar concerns as the Wells Fargo analysts, Baird analysts additionally noted the new and disruptive developments in Google Search that had just been presented at the Google I/O developer conference. On this news, the price of Reddit's common stock fell $9.79 per share, or 9.3%, from a closing price of $105.64 per share on May 20, 2025, to a closing price of $95.85 per share on May 21, 2025. For more information on the Reddit class action go to: About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information: Bragar Eagel & Squire, Walker, Esq. Marion Passmore, Esq.(212) 355-4648 [email protected]
Business Upturn
an hour ago
- Business Upturn
UNITEDHEALTH CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against UnitedHealth Group Incorporated and Encourages Investors to Contact the Firm
NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against UnitedHealth Group Incorporated ('UnitedHealth' or the 'Company') (NYSE: UNH) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired UnitedHealth securities between December 3, 2024 and April 16, 2025, both dates inclusive (the 'Class Period'). Investors have until July 7, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) UnitedHealth had, for years, engaged in a corporate strategy of denying health coverage in order to boost its profits, and ultimately, its share price; (2) this anti-consumer (and at times unlawful) strategy resulted in regulatory scrutiny (as well as public angst) against UnitedHealth, which ultimately resulted in the murder of Brian Thompson ('Thompson'); (3) animus towards UnitedHealth was such that, subsequent to the murder of Thompson, many Americans openly celebrated his demise, expressed admiration for his accused killer, and/or otherwise demanded that UnitedHealth change its strategy even if they condemned Thompson's killing; (4) the foregoing regulatory and public outrage caused UnitedHealth to change its corporate practices; (5) notwithstanding the foregoing, UnitedHealth recklessly stuck with the guidance it issued the day before Thompson's murder, which was unrealistic considering UnitedHealth's changing corporate strategies; and (6) as a result, defendants' public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. If you purchased or otherwise acquired UnitedHealth shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, Walker, Passmore, Esq.(212) 355-4648 [email protected]
Business Upturn
an hour ago
- Business Upturn
VESTIS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Vestis Corporation and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Attorney Brandon Walker Encourages Investors Who Suffered Losses In Vestis (VSTS) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Vestis between May 2, 2024, to May 6, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Vestis Corporation ('Vestis' or the 'Company') (NYSE:VSTS) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Vestis securities between May 2, 2024, to May 6, 2025, both dates inclusive (the 'Class Period'). Investors have until August 8, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Vestis' ability to grow its business; notably that Vestis would be unable to execute on planned strategic initiatives to drive purported improvements to the customer experience and its onboarding efforts in order to drive new customer growth, increased customer retention, and increased revenue from existing customers. On May 7, 2025, Vestis announced its financial results for the second quarter of fiscal 2025, withdrew its revenue and growth guidance for the full fiscal year 2025, and provided guidance for the third quarter of fiscal 2025 that fell significantly below market expectations. The Company attributed its poor results partially to 'lost business in excess of new business,' but primarily on 'lower adds over stops, which is how we describe volume changes with our existing customers.' The Company attributed its decision to pull full-year guidance and provide disappointing third quarter targets to the 'increasingly uncertain macro environment.' Following this news, the price of Vestis' common stock declined dramatically. From a closing market price of $8.71 per share on May 6, 2025, Vestis' stock price fell to $5.44 per share on May 7, 2025, a decline of about 37.54% in the span of just a single day. If you purchased or otherwise acquired Vestis shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, Walker, Passmore, Esq.(212) 355-4648 [email protected]
